News and Announcements
Invitation to Invest in Australia’s Most Exciting Cannabis Company
- Published March 20, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Recently the Founder of the Oz Medicann Group (OMG), John Leith launched the Series B capital raise with a cash injection of $600k. With increased revenues this financial year OMG will move from Early Stage Innovation to accelerated Growth. OMG’s impressive track record of bringing products to market, building brand awareness and customer loyalty and market ready innovative products will ensure future success and expansion into the global market.
OMG’s unique offering brings together patient centred health care, wellness and education. As an investor you will see the rewards of an integrated model which offers a number of revenue streams and opportunities in international markets. OMG has a diversified distribution model with over 3000 on line members, on-line sales and products in 350+ stockists across Australia.
Invest before June 30, 2020 to ensure that you maximise your investment through the ESIC Incentive program.
About Oz Medicann
OMG is a licenced patient-centric medicinal cannabis and hemp wellness company with a key focus on research, product development, education, cultivation and GMP standard manufacturing.
OMG is a diversified portfolio of companies comprising Oz Medicann Pharma, Educann and Hemp Oz and is supported by a team of medical practitioners, business leaders, marketing, sales and distribution expertise and innovation in new medicine.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
